Automated Insulin Delivery Patents

Automated insulin delivery (AID / closed-loop / 'artificial pancreas') patents cover closed-loop-control-algorithm innovations; dual-hormone and fully-closed-loop innovations; pump and on-body-delivery innovations; and interoperability and integration innovations — with IP held by pump makers and algorithm-driven AID companies (in the field that automates insulin dosing by linking a continuous glucose monitor to an insulin pump). WHAT IS AID: an automated insulin delivery system continuously reads glucose from a CGM (see continuous glucose monitor), runs a CONTROL ALGORITHM, and automatically adjusts insulin delivery from a pump — closing the loop between sensing and dosing (the 'artificial pancreas'). MAJOR AID PATENT HOLDERS: TANDEM DIABETES: the Control-IQ algorithm on the t:slim X2 pump (a leading hybrid closed-loop), and dosing-algorithm IP. INSULET: Omnipod 5 — an on-body (tubeless patch) automated system with the algorithm on the pod/phone. MEDTRONIC: the MiniMed 780G with SmartGuard (auto-correction and target automation), and a deep pump/AID estate. BETA BIONICS: the iLet Bionic Pancreas — a FULLY-CLOSED-LOOP system requiring no carb counting (just meal-size announcements), and DUAL-HORMONE (insulin + glucagon) work. OTHERS: Tidepool (the open-source Tidepool Loop, an FDA-cleared interoperable controller — community-driven), CamDiab (CamAPS FX algorithm), Bigfoot, and Ypsomed/CamDiab. The closed-loop control algorithm, dual-hormone, fully-closed-loop, and interoperability are the core AID patent domains — distinct from the CGM sensor and the pump hardware.

Control-algorithm innovations; predictive and meal-handling innovations; auto-correction and dosing innovations; and personalization and safety innovations represent core AID patent domains — though algorithm claims face §101 and are strongest tied to the insulin-delivery device and a method-of-treatment. CONTROL-ALGORITHM PATENTS: the algorithm that decides insulin delivery from glucose trends — model-predictive control MPC (predicting future glucose and dosing to keep it in range — Beta Bionics/academic), proportional-integral-derivative PID (Medtronic), fuzzy logic, and hybrid approaches; the specific control method tied to the pump and a glucose-management OUTCOME (a method of treating/controlling glucose) is more §101-durable than a bare algorithm. PREDICTIVE / MEAL-HANDLING PATENTS: predictive low-glucose suspend (cutting insulin before a predicted low), meal detection/handling (hybrid systems need a meal announcement; reducing or eliminating it is valuable), and exercise/activity modes. AUTO-CORRECTION / DOSING PATENTS: automatic correction boluses (delivering extra insulin for highs without user action — a key advance), basal modulation, and insulin-on-board management. PERSONALIZATION / SAFETY PATENTS: auto-tuning to the individual (learning insulin sensitivity), safety constraints/limits, and fault handling. The control algorithm (tied to the pump and glucose-control outcome), auto-correction boluses, and predictive suspend are the highest-value AID IP — claimed as device-integrated methods to survive §101.

Dual-hormone innovations; fully-closed-loop (no-meal-announcement) innovations; on-body and pump innovations; and interoperability and integration innovations represent additional AID patent domains — and reducing user burden (no carb counting) plus interoperable components are the frontiers. DUAL-HORMONE PATENTS: systems delivering BOTH insulin (to lower glucose) AND glucagon (to raise it — preventing hypoglycemia, mimicking the pancreas more fully — Beta Bionics) — the dual-hormone control algorithm, stable pumpable glucagon formulation, and dual-chamber pump are distinct, valuable IP. FULLY-CLOSED-LOOP PATENTS: eliminating carb counting/meal boluses (hybrid systems still need them) — algorithms that handle meals automatically from glucose response alone (Beta Bionics iLet uses only meal-size announcements), the holy grail of reducing patient burden. ON-BODY / PUMP PATENTS: tubeless on-body patch pumps (Insulet Omnipod), miniaturization, and pump mechanics/occlusion detection. INTEROPERABILITY PATENTS: the FDA's interoperable AID framework — iCGM (interoperable CGM), ACE pump (alternate controller enabled), and iController (interoperable algorithm) — letting mix-and-match components (Tidepool Loop as an interoperable controller); standardized interfaces and secure interoperability are valuable, patentable system IP. SECURITY PATENTS: cybersecurity for a life-critical connected device. Dual-hormone systems, fully-closed-loop (no meal announcement) algorithms, and interoperable controller/component designs are the highest-value next-generation AID IP because they reduce burden and enable an open ecosystem.

AID startup IP strategy must navigate Tandem Control-IQ, Medtronic, and Insulet algorithm/system estates, academic artificial-pancreas prior art (decades of MPC/PID closed-loop research — much is published), the CGM and pump component IP (your system uses a sensor and pump — see those FTO landscapes), a strong §101 constraint (dosing algorithms are abstract-idea-vulnerable unless tied to the device and a treatment outcome), FDA's life-critical-device and interoperability framework (clearance is a major moat), and a landscape where the algorithm-as-treatment, dual-hormone, fully-closed-loop, and interoperability are the durable assets; understand that closed-loop control concepts are partly academic prior art, so the durable IP is in specific control methods (tied to the pump/outcome), dual-hormone, fully-closed-loop meal handling, on-body design, and interoperability, and that FDA clearance and demonstrated glucose control matter as much as patents; identify whitespace in fully-closed-loop, dual-hormone, interoperability, and personalization. AID STARTUP IP STRATEGY: CONTROL CONCEPTS ARE PARTLY ACADEMIC — THE ALGORITHM-AS-TREATMENT, DUAL-HORMONE, AND FULLY-CLOSED-LOOP ARE THE IP: MPC/PID closed-loop is decades-old research, so patent the specific control method TIED TO THE PUMP and a glucose-control outcome (a method-of-treatment, §101-durable), dual-hormone control, fully-closed-loop meal handling, and on-body design; FULLY-CLOSED-LOOP (NO CARB COUNTING) IS HIGHEST-VALUE WHITESPACE: eliminating meal boluses/carb counting (Beta Bionics-style) hugely reduces patient burden — the algorithms that handle meals automatically are the most valuable, differentiated IP; DUAL-HORMONE (INSULIN + GLUCAGON) IS A DISTINCT, DEFENSIBLE PLATFORM: adding glucagon to prevent hypoglycemia (with stable formulation + dual-chamber pump) is high-value, distinct IP; INTEROPERABILITY (iCGM/ACE-PUMP/iCONTROLLER) ENABLES AN ECOSYSTEM PLAY: an interoperable controller (Tidepool-style) that works across sensors/pumps is a strategic, patentable system position; TIE ALGORITHMS TO THE DEVICE AND OUTCOME FOR §101: claim dosing as a device-integrated method of controlling glucose, not a bare algorithm; FDA CLEARANCE IS A LIFE-CRITICAL MOAT: AID is a high-risk device — clearance and safety record gate the market as much as IP; WHEN TO PATENT: NOVEL ALGORITHM/SYSTEM WITH MEASURED CONTROL: file once a system shows measured results (time-in-range % + hypoglycemia reduction + auto-correction performance + meal-handling burden + glucose variability) vs. hybrid-closed-loop baselines — measured time-in-range, hypoglycemia reduction, and user burden are the critical AID IP metrics; KEY FTO CHECKLIST: Tandem Control-IQ MPC algorithm t:slim; Insulet Omnipod 5 on-body algorithm; Medtronic 780G SmartGuard PID auto-correction; Beta Bionics iLet fully-closed-loop + dual-hormone insulin+glucagon; Tidepool Loop interoperable controller; CamDiab CamAPS; MPC/PID/fuzzy control (§101-tied-to-pump/outcome, academic prior art); predictive low-glucose suspend; auto-correction bolus; meal detection/handling no-carb-counting; dual-chamber pump + stable glucagon; iCGM/ACE-pump/iController interoperability; CGM sensor + pump component FTO; FDA life-critical clearance + cybersecurity.